Hims Is Begging Customers to Lobby the FDA to Keep Its Ozempic Knockoffs Legal

Image by Futurism You know Hims, right? It's the next-gen telehealth startup famous for taking the eye contact out of erectile dysfunction treatment. Of course, bedroom pills aren't all Hims peddles. The Uberized men's health app also offers hair loss treatment, STD meds, mental health services and GLP-1 weight loss treatments — though that's now going away. Fueled by global demand and slow production, 2024 was the year of the GLP-1 shortage. Originally used to treat type 2 diabetes, GLP-1 agonists like semaglutide and tirzepatide slow digestion and give users a feeling of satiety after eating less. Supply issues finally started to ease late in 2024, as compounded semaglutide — "copycats" of the patented stuff like Ozempic and Zepbound — began to flood the market when the FDA temporarily paused some regulations. Fast forward a few months, and those FDA regulations are back in full swing, along with a couple of court rulings that could end the copycat market for good. That's bad new ... Read full article.